Compare CSIQ & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSIQ | CGEM |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | Canada | United States |
| Employees | 17113 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 873.4M |
| IPO Year | 2006 | 2020 |
| Metric | CSIQ | CGEM |
|---|---|---|
| Price | $12.64 | $14.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $17.36 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 2.5M | 713.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.95 | N/A |
| Revenue Next Year | $13.58 | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.85 | $5.68 |
| 52 Week High | $34.59 | $16.74 |
| Indicator | CSIQ | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 53.58 |
| Support Level | $11.00 | $11.75 |
| Resistance Level | $13.73 | $16.74 |
| Average True Range (ATR) | 0.83 | 0.97 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 29.35 | 64.11 |
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.